Medical News

RSS

Research reveals link between repeated anaesthesia and memory impairment

There is a link between repeated anaesthesia in children and memory impairment, though physical activity can help to form new cells that improve memory, reveals new research from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

9 Mar 2010

Medica Research Institute launched for applying innovation to healthcare delivery

Medica today announced the launch of the Medica Research Institute as a non-profit company that will serve as the research arm within the broader organization. Built on the principals of systematic investigation, some potential areas of study include health services research, comparative effectiveness research and clinical trial studies.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

HDI announces results of Rapid Maternal Mortality and Obstetric Fistula Prevention Project

In honor of the 100th anniversary of International Women's Day, Health & Development International (HDI) announced the results of its Rapid Maternal Mortality and Obstetric Fistula Prevention Project today, in advance of its second hosted global meeting on this topic to be held at The Carter Center in Atlanta on March 9 and 10.

8 Mar 2010

GTA's stockholders voted to approve merger between GTA and Pernix Therapeutics

Golf Trust of America, Inc. announced that GTA's stockholders voted to approve the four proposals that were conditions to closing the previously-announced merger between GTA and Pernix Therapeutics, Inc. at a Special Meeting of Stockholders held earlier today.

8 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

Obama rallies Pa. audience, challenges insurers in health reform speech

"Trying to rally the public and put more pressure on Congress to act quickly, President Obama on Monday took to the road to castigate insurance companies and urged voters to lobby for passage of the healthcare overhaul," the Los Angeles Times reports.

8 Mar 2010

Exposure to BPA during pregnancy causes permanent abnormalities in uterus of offspring

Researchers at Yale School of Medicine have discovered that exposure during pregnancy to Bisphenol A (BPA), a common component of plastics, causes permanent abnormalities in the uterus of offspring, including alteration in their DNA. The findings were reported in the March issue of Journal of the Federation of American Societies for Experimental Biology.

8 Mar 2010

Virginia bill may prompt state-federal fight over insurance mandate

A bill in the Virginia state legislature could upend a critical provision of the Democrats' health overhaul and open the door for a fresh battle over the federal government's power over states, The Boston Globe reports.

8 Mar 2010

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology.

8 Mar 2010

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Taro Pharmaceutical Industries Ltd. today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fluorouracil Topical Cream USP, 5%.

8 Mar 2010

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX™ is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

8 Mar 2010

How health reform could affect 'young invincibles'

In this Kaiser Health News story, produced in collaboration with USA Today, KHN staff writer Phil Galewitz writes about how the so-called young invincibles would be impacted by pending health reform proposals.

8 Mar 2010

FDA grants Axis Surgical Technologies marketing clearance for C-MOR Visualization Device

Axis Surgical Technologies, Inc., announced today that it has received 510(k) clearance from the Food and Drug Administration to market their C-MOR™ Visualization Device for use in diagnostic and operative arthroscopic and endoscopic procedures. The self-contained portable direct-imaging tool provides illumination and visualization of an interior cavity through either a natural or surgical opening.

8 Mar 2010

Fact check: Do 15,000 people lose insurance every day?

CNN's Political Ticker blog fact checks a statement made by Health and Human Services Secretary Kathleen Sebelius on NBC's "Meet the Press" Sunday. Sebelius said that "15,000 people a day lose their insurance."

8 Mar 2010

State of Pennsylvania awards Medicaid managed care contract to Aetna Better Health

The State of Pennsylvania notified Aetna that it has awarded a Medicaid managed care contract to Aetna Better Health,SM Aetna’s Medicaid business.

8 Mar 2010

White House emphasizes rising health insurance costs as reason for reform

The Los Angeles Times analyzes how insurance costs became a focal point: "The Democrats' bill was in serious trouble when news broke of planned rate hikes by the California insurer. ... Anthem Blue Cross was seeking double-digit rate increases for many of its 800,000 individual policyholders. Company executives had little reason to worry. Insurers can raise premiums in the individual market as often -- and as much -- as they like, within certain guidelines. For years, such requests were routinely approved."

8 Mar 2010

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Rcadia Medical Imaging today announced that it has received a CE Mark for the COR Analyzer® System, its proprietary software that helps identify patients with significant CAD (Coronary Artery Disease) by a fully automatic analysis of coronary CT angiography (cCTA) studies. The CE Mark allows the company to market the system in the European Union and other countries that accept the CE Mark registration. The COR Analyzer is marketed in the U.S. under 510(k) clearance and Rcadia was named 2009 Best New Radiology Vendor by AuntMinnie.com.

8 Mar 2010

Reconciliation update: Some Dems, GOP and industry groups wary health bill strategy

The Los Angeles Times: "Obama's signature ability to inspire fellow Democrats and Pelosi's well-honed ability to read their parochial needs will be tested as they tackle the job of finding the last stubborn votes for the healthcare bill. ... "Under the Democrats' strategy, the House would pass the Senate's version of the bill. Then both chambers would approve changes under the budget reconciliation process, which could pass the Senate with a simple 51-vote majority. Democrats hope to finish by the end of the month" (Hook and Levey, 3/8).

8 Mar 2010

Response Genetics to raise $4M from private placement of over 3M newly issued shares

Response Genetics, Inc. announced today that it has entered into a purchase agreement with certain new and existing investors and certain funds managed by Lansdowne Partners Limited Partnership to raise approximately $4 million from the private placement of 3,005,349 newly issued shares of its common stock, at a purchase price of $1.31 per share. The signing of the purchase agreement occurred on Friday, March 5, 2010. We expect the final closing of the shares will occur on Monday, March 8, 2010.

8 Mar 2010

Medical News

Research reveals link between repeated anaesthesia and memory impairment

Medica Research Institute launched for applying innovation to healthcare delivery

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

HDI announces results of Rapid Maternal Mortality and Obstetric Fistula Prevention Project

GTA's stockholders voted to approve merger between GTA and Pernix Therapeutics

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

Obama rallies Pa. audience, challenges insurers in health reform speech

Exposure to BPA during pregnancy causes permanent abnormalities in uterus of offspring

Virginia bill may prompt state-federal fight over insurance mandate

Prostate-specific dietary supplements discouraged during radiation therapy treatments: Study

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

How health reform could affect 'young invincibles'

FDA grants Axis Surgical Technologies marketing clearance for C-MOR Visualization Device

Fact check: Do 15,000 people lose insurance every day?

State of Pennsylvania awards Medicaid managed care contract to Aetna Better Health

White House emphasizes rising health insurance costs as reason for reform

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Reconciliation update: Some Dems, GOP and industry groups wary health bill strategy

Response Genetics to raise $4M from private placement of over 3M newly issued shares

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News